| # | Diagnostics | Indication | Prototyping/ Optimization | Service Model Readiness* | Valid Clinical Association | Analytical Validation | Clinical Validation | Pre-market | Launch |
|---|---|---|---|---|---|---|---|---|---|
| 1) | QGCTest_HGSOC | Ovarian Cancer(HGSOC) |
|
||||||
| 2) | QGCTest_Breast | Breast Cancer(HER-2) |
|
||||||
| 3) | QGCTest_NSCLC | Lung Cancer(NSCLC) |
|
||||||
| 4) | QGCTest_SCLC | Lung Cancer(SCLC) |
|
||||||
| 5) | QGCTest_CRC | Colorectal Cancer(CRC) |
|
||||||
| 6) | QGCTest_HCC | Liver Cancer(HCC) |
|
||||||
| 7) | QGCTest_Leukemia | Leukemia |
|
||||||
| 8) | QGCTest_Prostate | Prostate Cancer |
|
||||||
| 9) | QGCTest_Myeloma | Myeloma Cancer |
|
||||||
Ovarian QGCT® is a tissue RNA-based ovarian cancer screening test for High Grade Serous Ovarian Cancer Chemoresistance.
Ovarian cancer is one of the leading causes of cancer-related death worldwide. The most dominant subtype, High Grade Serous Ovarian Cancer (HGSOC), accounts for 70-80% of ovarian cancer deaths.
In the past 30 years, the standard treatment for HGSOC has been platinum-based chemotherapy as patients have strong sensitivity to this treatment, with response rates reaching 85%.
However, greater than 80% of ovarian cancer patients experience relapse at some stage after treatment. In response, patients are typically treated with platinum-based chemotherapies again, but these chemotherapies exhibit diminishing effectiveness with each treatment. Ultimately, 80-90% of patients with HGSOC eventually develop chemoresistance, and thus results in mortality.
Due to the prevalence and high mortality that results from HGSOC chemoresistance, our Ovarian QGCT®, being able to gain a deeper understanding of its mechanisms and causes, will be beneficial for developing more effective treatments for HGSOC patients.
BYQM offers the Ovarian QGCT® to help patients and doctors understand what treatment options are right for them, including if they are likely to benefit from chemotherapy.
Our vision is to eradicate cancer and the suffering it causes through the tests that detect at the earliest of diagnosis and provide guidance for successful treatment.
Breast QGCT® is a tissue RNA-based test for recurrence of HER2 positive breast cancer after target therapy
Breast cancer is the most frequent cancer in women worldwide and is one of the leading causes of cancer-related deaths in both sexes. About 25% of all breast cancer cases are HER2-positive, characterized by high recurrence and mortality rates.
In the last twenty years, the development of HER2-targeted therapy has significantly improved patient survival and drastically transformed the course of breast cancer treatment. While most patients are therapy-responsive, some are not, and a subset of those who initially responded experience tumor relapse. This means that there is heterogeneity in treatment response.
We have established genome-wide co-expression patterns unique to non-relapse and relapse patients. Comparison of their gene co-expression profiles reveals distinctive properties and mechanisms pertaining to their state and improve our understanding of relapse biology in HER2-positive breast cancer.
BYQM offers the Breast QGCT® to help patients and doctors understand the risk of recurrence. The test looks at the underlying biology of a patient’s tumor so patients can choose a treatment that fits their unique situation.
BYQM offers the Lung QGCT® to help patients and doctors understand the risk of poor survival. The test, which look at the underlying biology of the patients’s tumor, provides precise diagnosis so patients can choose a treatment that fits their unique situation and overall they have better prognosis and quality of life ahead
BYQM offers the SCLC QGCT® to help patients and doctors understand the risk of high mortality. The test, which look at the underlying biology of the patient’s tumor, provides early and precise diagnosis so patient can choose new SCLC therapies to combatting chemotheray resistance.
Colorectal cancer QGCT® is a tissue RNA-based test for recurrence of colorectal cancer after surgery.
Colorectal cancer is a third most prevalent carcinoma worldwide and current tumor staging fails to accurately predict cancer recurrence, contributing to poor five year survival rate
We have established the genome-wide co-expression patterns unique to high and low recurrence risk colorectal cancer patients. Comparison of their gene co-expression profiles reveals distinctive properties and mechanisms pertaining to their state and improve our understanding of the recurrence biology in colorectal cancer.
BYQM offers the Colorectal cancer QGCT® to help the patients and doctors understand their risks of recurrence. The test looks at the underlying biology of the patients’ tumors so patients , having precise diagnosis, can choose treatment that fit their unique situation and overall have better prognosis, survival and quality of life ahead.
Hepatoma carcinoma (HCC) QGCT® is a tissue RNA-based test for pathogenesis of HCC
HCC is the second leading cause of cancer-related death around the globe and nearly 60% of all reported HCC cases worldwide are from Chinese. Multiple risk factors are involved in the etiology of HCC, which accounts for approximately 75% of HCC globally. With high mortality rate and poor diagnosis, HCC remains as a challenge.
We have established the genome-wide co-expression patterns unique to HCC and HBV-associated HCC. Comparison of the gene co-expression patterns reveals distinctive properties and mechanisms pertaining to their state and improve our understanding of HCC and HBV-associated HCC.
BYQM offers the HCC QGCT® to help patients and doctors understand the pathogenegis of HCC. The test, which looks at the underlying biology of the patients’ tumors, so patients, having early and precise diagnosis, can choose treatment that fits their unique situation and overall have better prognosis, survival rate and quality of life ahead.